U.S. markets closed

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.54-1.17 (-5.94%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close19.71
Open19.67
Bid18.40 x 900
Ask18.88 x 1000
Day's Range18.36 - 19.67
52 Week Range9.03 - 31.54
Volume120,349
Avg. Volume272,990
Market Cap1.648B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.16
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test
    GlobeNewswire

    Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

    The CE Mark and comparative data highlight the Company’s capability in providing high quality and consistent testing productsBEIJING, July 13, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received CE Mark for its 8-gene Lung Cancer Assay. Sepa

  • Genetron Partners With World Economic Forum; Shares Tank 9%
    SmarterAnalyst

    Genetron Partners With World Economic Forum; Shares Tank 9%

    Genetron Holdings Limited (GTH), one of the leading players in precision oncology in China, recently announced that it has entered into a partnership with the World Economic Forum (WEF). Under the partnership, Genetron will work for the Health and Healthcare Platform of the WEF. Following the news release, shares of the company declined 8.6% to close at $18.55 in Friday’s trading session. As a partner, Genetron will provide its technologies, industry expertise and insights to the WEF. The aim of

  • Genetron Health Enters into Platform Partnership with World Economic Forum
    GlobeNewswire

    Genetron Health Enters into Platform Partnership with World Economic Forum

    BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform. Genetron Health, as a platform partner, will contribute its research insights, technologies